Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab access study in selected rare adult cancers
2016-002257-37Phase 2Completed
- Sponsor
- Unicancer
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in non-clear cell renal cell carcinoma (nccRCC), head and neck cancer (HNC), cutaneous malignancy and 2 more, sponsored by Unicancer. Primary endpoint: Objective response rate. Started Feb 2017; status: completed.
02
Drugs
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)head and neck cancer (HNC)cutaneous malignancymicrosatellite instability-high cancerpenile cancer
Beyond the preview
Go deeper on 2016-002257-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002257-37.